Indaptus Therapeutics, Inc. (INDP) Financial Statements (2024 and earlier)

Company Profile

Business Address 3 COLUMBUS CIRCLE
NEW YORK, NY 10019
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

9/30/2023
MRQ
12/31/2022
12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments26,432,80939,132,165
Cash and cash equivalents9,626,80039,132,165
Short-term investments 16,806,009 
Prepaid expense730,523957,954
Asset, held-for-sale, not part of disposal group  148,400
Other undisclosed current assets80,910148,699
Total current assets:27,244,24240,387,218
Noncurrent Assets
Operating lease, right-of-use asset79,294169,088
Property, plant and equipment2,0193,800
Other noncurrent assets738,25116,477
Total noncurrent assets:819,564189,365
TOTAL ASSETS:28,063,80640,576,583
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2,796,8824,246,592
Employee-related liabilities1,371,136
Accounts payable1,378,3162,637,806
Accrued liabilities1,418,566237,650
Other undisclosed current liabilities636,459357,549
Total current liabilities:3,433,3414,604,141
Noncurrent Liabilities
Long-term debt and lease obligation:  72,862
Liabilities, other than long-term debt  
Operating lease, liability 72,862
Other undisclosed noncurrent liabilities  (72,862)
Total noncurrent liabilities: 72,862
Total liabilities:3,433,3414,677,003
Equity
Equity, attributable to parent24,630,46535,899,580
Common stock84,01182,586
Additional paid in capital54,443,70551,487,881
Accumulated other comprehensive income 96,434 
Accumulated deficit(29,993,685)(15,670,887)
Total equity:24,630,46535,899,580
TOTAL LIABILITIES AND EQUITY:28,063,80640,576,583

Income Statement (P&L) (USD)

9/30/2023
TTM
12/31/2022
12/31/2021
Operating expenses(14,910,906)(7,729,108)
Operating loss:(14,910,906)(7,729,108)
Nonoperating income588,10817,722
Loss from continuing operations:(14,322,798)(7,711,386)
Loss before gain (loss) on sale of properties:(7,711,386)
Net loss available to common stockholders, diluted:(14,322,798)(7,711,386)

Comprehensive Income (USD)

9/30/2023
TTM
12/31/2022
12/31/2021
Net loss:(14,322,798)(7,711,386)
Comprehensive loss:(14,322,798)(7,711,386)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent96,434 
Comprehensive loss, net of tax, attributable to parent:(14,226,364)(7,711,386)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: